Allarity Therapeutics, Inc.

NASDAQ: ALLR · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0001860657Reports USD

#952 of 1,394 Healthcare companies by revenue

EA Score

24D

FH 32DQ 12GM —SS 28

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, market scale · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$345.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$11.2M

Employees

Market cap

$20.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$320.0k$320.0k2025

Net income-$11.2M-$11.2M2025

Operating income-$12.6M-$12.6M2025

Total assets$18.3M$18.3M2025

Liabilities$8.4M$8.4M2025

Equity$9.8M$9.8M2025

Revenue by segment

Filed disclosures · FY2025

By product

License100%

By geography

Not disclosed.

The read

Allarity Therapeutics, Inc. booked $320.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -3509.7% net margin.

Peers · Healthcare

MediPharm Labs Corp.61C Serina Therapeutics, Inc.41D BetterLife Pharma Inc.——ZIVO Bioscience, Inc.——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M75B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B67B PTC Inc.$2.7B84B+

Key facts

CEOThomas H. Jensen

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: ALLR

Employees6

IPO date2021-12-21

Latest filings

8-K2026-07-01 8-K2026-06-22 8-K2026-06-02 10-Q2026-05-15 8-K2026-05-08 8-K2026-05-06 DEF 14A2026-04-30 8-K2026-04-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.